BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11956276)

  • 1. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
    Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
    J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
    Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
    J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of high-dose
    Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
    J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
    Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
    Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
    Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
    Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
    Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.
    Goldberg SS; DeSantes K; Huberty JP; Price D; Hasegawa BH; Reynolds CP; Seeger RC; Hattner R; Matthay KK
    Med Pediatr Oncol; 1998 Jun; 30(6):339-46. PubMed ID: 9589082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
    Hamidieh AA; Beiki D; Paragomi P; Fallahi B; Behfar M; Fard-Esfahani A; Hosseini AS; Shamshiri A; Eftekhari M; Ghavamzadeh A
    Pediatr Transplant; 2014 Aug; 18(5):510-7. PubMed ID: 24814429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
    Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
    Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
    de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
    Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study.
    Klingebiel T; Bader P; Bares R; Beck J; Hero B; Jürgens H; Lang P; Niethammer D; Rath B; Handgretinger R
    Eur J Cancer; 1998 Aug; 34(9):1398-402. PubMed ID: 9849423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Tait D; Meller S
    J Nucl Biol Med (1991); 1991; 35(4):228-31. PubMed ID: 1823824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.
    Miano M; Garaventa A; Pizzitola MR; Piccolo MS; Dallorso S; Villavecchia GP; Bertolazzi C; Cabria M; De Bernardi B
    Bone Marrow Transplant; 2001 Mar; 27(6):571-4. PubMed ID: 11319584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.